VRTX Vertex Pharmaceuticals Incorporated Stock Quote

VRTX [NASD]

Index	S&P 500	P/E	17.98	EPS (ttm)	10.51	Insider Own	0.20%	Shs Outstand	259.37M	Perf Week	-10.50%
Market Cap	54.94B	Forward P/E	14.96	EPS next Y	12.63	Insider Trans	-13.79%	Shs Float	258.52M	Perf Month	-12.95%
Income	2.76B	PEG	1.39	EPS next Q	2.30	Inst Own	93.60%	Short Float	1.57%	Perf Quarter	-13.71%
Sales	6.41B	P/S	8.56	EPS this Y	128.00%	Inst Trans	-0.99%	Short Ratio	2.15	Perf Half Y	-15.70%
Book/sh	34.62	P/B	5.46	EPS next Y	14.53%	ROA	24.30%	Target Price	285.39	Perf Year	-29.43%
Cash/sh	23.82	P/C	7.93	EPS next 5Y	12.90%	ROE	33.20%	52W Range	188.01 - 306.08	Perf YTD	-20.04%
Dividend	-	P/FCF	18.03	EPS past 5Y	45.30%	ROI	26.40%	52W High	-37.90%	Beta	0.66
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	43.20%	Gross Margin	88.10%	52W Low	1.10%	ATR	5.40
Employees	3400	Current Ratio	4.40	Sales Q/Q	13.80%	Oper. Margin	47.10%	RSI (14)	29.52	Volatility	2.91% 2.06%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	9.00%	Profit Margin	43.10%	Rel Volume	1.35	Prev Close	188.97
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Apr 29 AMC	Payout	0.00%	Avg Volume	1.88M	Price	190.07
Recom	1.80	SMA20	-8.84%	SMA50	-10.67%	SMA200	-16.08%	Volume	1,060,136	Change	0.58%

Jun-11-21

Downgrade

Daiwa Securities

Outperform → Neutral

$210

Feb-23-21

Upgrade

Robert W. Baird

Neutral → Outperform

$220 → $252

Feb-02-21

Reiterated

H.C. Wainwright

Buy

$315 → $275

Dec-30-20

Initiated

Daiwa Securities

Outperform

$250

Nov-30-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$247 → $267

Nov-20-20

Initiated

Bernstein

Outperform

$225

Oct-28-20

Initiated

UBS

Buy

$287

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$295 → $315

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$300

Apr-30-20

Reiterated

H.C. Wainwright

Buy

$270 → $295

Apr-28-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$250 → $260

Mar-04-20

Initiated

Barclays

Overweight

$271

Jan-31-20

Downgrade

Robert W. Baird

Outperform → Neutral

$210 → $230

Nov-19-19

Upgrade

Guggenheim

Neutral → Buy

$252

Nov-12-19

Initiated

SunTrust

Buy

$235

Oct-17-19

Resumed

BofA/Merrill

Buy

$220

Sep-03-19

Upgrade

Goldman

Neutral → Buy

$226 → $254

Aug-01-19

Downgrade

Needham

Buy → Hold

May-23-19

Resumed

Citigroup

Buy

$205

May-21-19

Initiated

Credit Suisse

Outperform

$209

Jun-16-21 06:43AM	Vertex in a Vortex, But Recent Failures Can Be Turned Around TipRanks
04:49AM	Why Are Analysts Still Bullish About Vertex Pharmaceuticals After VX-864 Update? TipRanks
Jun-15-21 08:35PM	2 Stocks That Are Flirting With a Bottom; Analysts Say Buy TipRanks
06:55AM	Can Vertex Pharmaceuticals Recover From Its Latest Setback? Motley Fool
05:40AM	Is It Too Late to Buy Vertex Pharmaceuticals Stock? Motley Fool
04:37AM	CRISPR on the Cutting Edge of Gene Editing Technology TipRanks
Jun-14-21 05:50PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
03:45PM	Hedge Funds Have Never Been This Bullish On Vertex Pharmaceuticals Incorporated (VRTX) Insider Monkey
10:50AM	CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data Zacks
09:38AM	Company News for Jun 14, 2021 Zacks
Jun-11-21 04:15PM	Biotech Finds Market Love at Last as Meme Traders, FDA Converge Bloomberg -10.96%
04:12PM	Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock Investor's Business Daily
01:42PM	Dow Slips, Small Caps Lead Upside, Nasdaq Holds Gain; These Biotech Stocks Make Notable Moves Investor's Business Daily
11:35AM	VRTX Stock: The Disappointing News Sending Vertex Pharma Shares Lower InvestorPlace
10:42AM	Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate Zacks
10:33AM	Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials Benzinga
09:24AM	Why Vertex Pharmaceuticals Stock Is Getting Hammered Today Motley Fool
08:55AM	Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising Barrons.com
08:46AM	Vertex Pharmaceuticals stock tumbles to pace S&P 500 losers after disappointing drug trial data MarketWatch
06:45AM	Wait a Few Days to Trade Vertex So You Don't Get Your Face Ripped Off TheStreet.com
06:23AM	Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles Benzinga
05:52AM	Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner Motley Fool
04:36AM	Premarket Movers Friday: Vertex Pharma, AMC, Dave & Buster's TheStreet.com
03:05AM	Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at European Hematology Association Annual Meeting Business Wire
02:43AM	Vertex Pharmaceuticals Seen as Buying Opportunity as Stock Plunges TheStreet.com
Jun-10-21 06:21PM	Vertex Pharma Stumbles In Rare-Disease Effort, Buoying Rival Arrowhead Pharma Investor's Business Daily
04:03PM	Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency Business Wire
02:23PM	Vertex Halts Further Study of AATD Drug TheStreet.com
12:12PM	Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children Zacks
06:06AM	Ditch Dogecoin: These Stocks Are Screaming Buys in June Motley Fool
Jun-09-21 02:37PM	Vertex Pharmaceuticals Nabs Key FDA Approval in Cystic Fibrosis Motley Fool
11:04AM	CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Business Wire
08:46AM	Vertex Pharma's Trikafta Triplet Therapy Wins FDA Approval For Expanded Use In Children 6-11 Years With Cystic Fibrosis Benzinga
Jun-07-21 05:45PM	Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know Zacks
Jun-04-21 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
Jun-03-21 10:20AM	Battle of the $54 Billion Assets: Buy This, Not Dogecoin Motley Fool
05:51AM	3 Value Stocks That'll Make You Richer in June (and Beyond) Motley Fool
Jun-02-21 09:03AM	3 Biotech Stocks With Huge Catalysts in June Motley Fool
May-31-21 06:01AM	The Best Biotech Stocks to Buy With $500 Motley Fool
May-29-21 08:51AM	3 Stocks to Hold for the Next 20 Years Motley Fool
May-26-21 06:10AM	Don't Wait For a Market Crash: These 2 Top Stocks Are On Sale Motley Fool
06:05AM	4 Unstoppable Healthcare Stocks to Buy on the Dip Motley Fool
May-22-21 06:25AM	Is Vertex Pharmaceuticals a Buy? Motley Fool
05:51AM	A Stock Market Crash May Be Near: 3 Stocks to Buy Hand Over Fist When It Happens Motley Fool
May-19-21 08:26AM	Does Vertex Pharmaceuticals (NASDAQ:VRTX) Deserve A Spot On Your Watchlist? Simply Wall St.
06:00AM	3 Biotech Stocks You'll Be Glad You Bought at These Prices Motley Fool
May-18-21 06:43AM	Concert Pharma Sells VX-561-Related Milestones To Vertex For $32M Benzinga
May-16-21 05:51AM	4 Surefire Value Stocks to Buy for a Biden Bull Market Motley Fool
May-14-21 05:52AM	Dogecoin's Biggest Weakness Is the Greatest Strength for These 2 Stocks Motley Fool
May-13-21 05:51AM	Forget Dogecoin: These Unstoppable Stocks Are Much Smarter Buys Motley Fool
05:31AM	3 Mistakes to Avoid When Investing in Biotech Stocks Motley Fool
May-12-21 11:00AM	Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress GlobeNewswire
06:14AM	3 Healthcare Stocks That Might Soar if Biden Gets This Part of His Budget Approved Motley Fool
May-10-21 09:01AM	Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13 Business Wire
05:51AM	5 Growth Stocks Rocketing Up My Prospective Buy List Motley Fool
May-07-21 05:50PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
10:24AM	Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View Zacks
May-04-21 07:10AM	Was The Smart Money Right About Vertex Pharmaceuticals (VRTX)? Insider Monkey
06:00AM	This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon Motley Fool
May-01-21 06:30AM	Forget Penny Stocks: Buy These 2 Stocks Instead Motley Fool
06:10AM	Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? Motley Fool
Apr-30-21 08:12AM	Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y Zacks
06:50AM	Have $1,000 to Invest? Buy These 2 Growth Stocks Right Now Motley Fool
06:05AM	Here's How Vertex Pharmaceuticals Beat Expectations in Q1 Motley Fool
06:01AM	3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners Motley Fool
Apr-29-21 10:01PM	Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript Motley Fool
05:25PM	Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates Zacks
05:00PM	Vertex Stock Muted After Beating Quarterly Views; What Could Spark Shares? Investor's Business Daily
04:01PM	Vertex Reports First-Quarter 2021 Financial Results Business Wire
Apr-28-21 12:18PM	Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News Zacks
09:56AM	CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y Zacks
07:30AM	Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene Business Wire
Apr-26-21 02:47PM	Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward Motley Fool
09:54AM	What's in Store for Vertex (VRTX) This Earnings Season? Zacks
08:30AM	Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001 for Transfusion-Dependent Beta Thalassemia GlobeNewswire
07:29AM	Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development Business Wire
Apr-25-21 06:00AM	3 Top Biotech Picks to Buy and Hold for the Next 10 Years Motley Fool
Apr-23-21 08:09AM	Is a Beat in Store for CRISPR (CRSP) This Earnings Season? Zacks
06:25AM	Is Vertex Pharmaceuticals a Good Stock to Buy Right Now? Motley Fool
Apr-22-21 12:33PM	Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:06AM	Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic Therapies Benzinga
08:00AM	Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing Business Wire
Apr-21-21 02:54PM	Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates Zacks
08:55AM	Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership Zacks
07:59AM	Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia MarketWatch
06:40AM	3 Top Value Stocks in Healthcare to Buy Right Now Motley Fool
Apr-20-21 05:50PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
04:29PM	Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics Motley Fool
07:15AM	Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia GlobeNewswire
Apr-19-21 09:01AM	Vertex to Announce First-Quarter 2021 Financial Results on April 29 Business Wire
Apr-18-21 06:06AM	The Growth Stock Sale of 2021 Has Arrived: 3 Stocks to Buy Now Motley Fool
Apr-17-21 09:01AM	A Star-Laden Biotech SPAC Worth Considering Motley Fool
07:00AM	3 Cathie Wood Stocks You Can Buy at a Bargain Right Now Motley Fool
Apr-16-21 09:12AM	The Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Is Up 155% And Shareholders Are Boasting About It Simply Wall St.
06:04AM	4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla Motley Fool
Apr-14-21 05:50PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
Apr-13-21 05:50AM	5 Value Stocks With 26% to 50% Upside, According to Wall Street Motley Fool
Apr-11-21 09:03AM	3 Critical Things Investors Should Look for Before Buying Clinical-Stage Biotech Stocks Motley Fool
Apr-08-21 04:20PM	Biotech Stocks Could Use A Win Will The First Quarter Offer That? Investor's Business Daily
Apr-07-21 06:01AM	3 Top Biotech Stocks to Buy in April Motley Fool

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bhatia Sangeeta N.	Director	Jun 02	Sale	209.69	559	117,216	5,191	Jun 04 04:03 PM
Arbuckle Stuart A	EVP, Chief Comm & Ops Officer	May 17	Sale	216.41	109	23,589	41,103	May 19 04:04 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 17	Sale	216.36	79	17,093	33,589	May 19 04:02 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 17	Sale	216.34	112	24,230	34,108	May 19 04:10 PM
Sachdev Amit	EVP, Chief Patient Officer	May 17	Sale	216.35	45	9,736	40,133	May 19 04:08 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 03	Sale	218.43	960	209,691	34,108	May 05 09:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Option Exercise	86.52	3,884	336,044	44,017	Apr 29 04:03 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Sale	216.06	3,884	839,193	40,133	Apr 29 04:03 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 05	Sale	214.14	1,686	361,046	35,834	Apr 07 04:04 PM
Liu Joy	SVP, General Counsel	Mar 05	Sale	209.69	5,141	1,078,018	8,253	Mar 08 04:10 PM
Silva Paul M	SVP & Chief Accounting Officer	Mar 01	Sale	211.45	2,782	588,255	9,884	Mar 02 04:07 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 25	Sale	213.47	1,080	230,551	14,884	Feb 26 04:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 25	Sale	213.42	3,586	765,307	40,133	Feb 26 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 25	Sale	213.38	3,028	646,125	30,837	Feb 26 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 25	Sale	213.54	3,634	775,989	41,103	Feb 26 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 25	Sale	213.39	3,028	646,139	33,589	Feb 26 04:03 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 18	Sale	211.83	4,295	909,828	16,828	Feb 19 04:21 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 18	Sale	211.83	9,264	1,962,366	46,665	Feb 19 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 18	Sale	211.83	7,825	1,657,556	36,281	Feb 19 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 18	Sale	211.82	7,825	1,657,481	47,635	Feb 19 04:08 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 18	Sale	211.83	7,825	1,657,590	39,033	Feb 19 04:05 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 11	Sale	210.55	4,460	939,068	63,542	Feb 16 04:20 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 11	Sale	210.57	1,498	315,437	23,863	Feb 16 04:24 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 11	Sale	210.56	1,686	355,012	38,864	Feb 16 04:22 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 11	Sale	210.56	4,318	909,179	50,346	Feb 16 04:15 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 11	Sale	210.55	5,156	1,085,593	61,700	Feb 16 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 11	Sale	210.54	5,283	1,112,274	53,098	Feb 16 04:02 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Option Exercise	86.52	1,930	166,984	59,157	Feb 09 07:44 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Sale	215.00	1,930	414,950	57,227	Feb 09 07:44 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Option Exercise	86.52	1,554	134,452	71,511	Feb 05 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Option Exercise	86.52	400	34,608	57,627	Feb 05 04:52 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Sale	216.56	400	86,624	57,227	Feb 05 04:52 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Sale	213.74	1,554	332,146	69,957	Feb 05 04:43 PM
Sachdev Amit	EVP, Chief Patient Officer	Nov 16	Sale	223.53	42	9,388	35,103	Nov 18 04:16 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 16	Sale	223.53	91	20,341	26,838	Nov 18 04:12 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 16	Sale	223.64	7	1,565	35,179	Nov 18 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 16	Sale	223.47	38	8,492	28,902	Nov 18 04:10 PM
SACHS BRUCE I	Director	Nov 10	Buy	217.36	15,000	3,260,465	26,210	Nov 12 08:18 AM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Option Exercise	86.52	2,330	201,592	29,168	Nov 06 04:09 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Sale	217.74	2,330	507,329	26,838	Nov 06 04:09 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Option Exercise	86.52	1,553	134,366	36,732	Nov 05 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Sale	211.92	1,553	329,115	35,179	Nov 05 04:16 PM
Bhatia Sangeeta N.	Director	Oct 05	Option Exercise	126.68	8,729	1,105,790	14,424	Oct 07 04:11 PM
Bhatia Sangeeta N.	Director	Oct 05	Sale	266.79	10,516	2,805,518	3,908	Oct 07 04:11 PM
Silva Paul M	SVP & Controller	Aug 06	Option Exercise	169.39	1,078	182,598	16,010	Aug 10 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Option Exercise	155.57	1,223	190,262	30,125	Aug 10 04:13 PM
Kewalramani Reshma	CEO & President	Aug 06	Option Exercise	179.68	2,073	372,482	28,699	Aug 10 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Option Exercise	155.57	1,223	190,262	28,061	Aug 10 04:22 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Sale	271.20	1,223	331,672	26,838	Aug 10 04:22 PM
Kewalramani Reshma	CEO & President	Aug 06	Sale	271.20	2,073	562,205	26,626	Aug 10 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Sale	271.19	1,223	331,663	28,902	Aug 10 04:13 PM
Silva Paul M	SVP & Controller	Aug 06	Sale	271.17	1,078	292,319	14,932	Aug 10 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Option Exercise	86.52	2,330	201,592	31,232	Aug 05 04:14 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Option Exercise	86.52	1,553	134,366	36,732	Aug 05 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Option Exercise	86.52	2,330	201,592	29,168	Aug 05 04:20 PM
Silva Paul M	SVP & Controller	Aug 03	Option Exercise	86.52	809	69,995	15,741	Aug 05 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Option Exercise	86.52	1,941	167,935	37,044	Aug 05 04:51 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Sale	278.28	1,941	540,137	35,103	Aug 05 04:51 PM
Silva Paul M	SVP & Controller	Aug 03	Sale	278.30	809	225,142	14,932	Aug 05 04:24 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Sale	278.28	2,330	648,402	26,838	Aug 05 04:20 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Sale	278.39	1,553	432,337	35,179	Aug 05 04:17 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Sale	278.24	2,330	648,290	28,902	Aug 05 04:14 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Option Exercise	90.29	2,125	191,866	28,963	Jul 15 04:41 PM
Silva Paul M	SVP & Controller	Jul 13	Option Exercise	90.29	860	77,649	15,792	Jul 15 04:51 PM
Silva Paul M	SVP & Controller	Jul 13	Sale	292.03	860	251,145	14,932	Jul 15 04:51 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Sale	292.05	2,125	620,610	26,838	Jul 15 04:41 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jul 10	Sale	293.15	700	205,206	16,126	Jul 14 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Option Exercise	173.51	2,786	483,403	37,965	Jul 09 04:13 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Sale	300.00	2,786	835,800	35,179	Jul 09 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Jun 30	Sale	286.15	32,792	9,383,304	2,261	Jul 02 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience